Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Clinical trial NCT05103332 · COMPLETED
Trial details
- NCT number
- NCT05103332
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-05
- Primary completion
- 2023-12-11
- Enrollment
- 663
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.